First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patients

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 595-602

  Smith, I E ^a   Pierga, J Y ^b   Biganzoli, L ^c   Cortes Funes H ^d   Thomssen, C ^e   Pivot, X ^f   Fabi, A ^g   Xu, B ^h   Stroyakovskiy, D ⁱ   Franke, F A ^j   Kaufman, B ^k   Mainwaring, P ^l   Pienkowski, T ^m   de Valk, B ⁿ   Kwong, A ^o   Gonzalez Trujillo J L ^p   Koza, I ^q   Petrakova, K ^r   Pereira, D ^s   Pritchard, K I ^t  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUT CURIE   (France)

^c Prato Hospital   (Italy)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^h CANCER HOSPITAL   (China)

ⁱ The Department of Healthcare of the City of Moscow   (Russian Federation)

^j Hospital de Caridade de Ijui   (Brazil)

^k Breast Cancer Unit   (Israel)

^l Mater Hospital   (Australia)

^m INSTITUTE OF ONCOLOGY   (Poland)

ⁿ ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^o UNIVERSITY OF HONG KONG   (Hong Kong)

^p Fundación Rodolfo Padilla   (Mexico)

^q CANCER RESEARCH INSTITUTE   (Slovakia)

^r MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^s PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^t DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

more..

Author keywords

Angiogenesis; Bevacizumab; First line; Metastatic breast cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BONE MARROW APLASIA; BREAST CANCER; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; FOLLOW UP; GENERAL CONDITION DETERIORATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INFECTION; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NAIL DISEASE; NAUSEA; NEPHROTIC SYNDROME; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SEPSIS; SIDE EFFECT; STOMATITIS; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

EID: 79952027747     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq430     Document Type: Article

References (20)

1. Nieves BJ, D'Amore PA, Bryan BA. The function of vascular endothelial growth factor. Biofactors 2009; 35: 332-337.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
3. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
4. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
5. Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-4972.
6. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009; 27 (Suppl): 15s (Abstr 1005).
7. Miller KD, Chap LI, Holmes FA et al. Randomized, phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
8. National Cancer Institute-Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006.
9. Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010; [Epub ahead of print].
10. Etienne-Grimaldi M-C, Formento P, Degeorges A et al. Impact of germinal vascular endothelial growth factor-A (VEGF-A) gene polymorphisms on pharmacodynamics of bevacizumab in metastatic breast cancer patients treated as first-line therapy: a French companion study of the open label international multicenter MO19391 trial. Proceedings of the American Association for Cancer Research Annual Meeting 2010, April 17-21, Washington, DC, USA (Abstr 2751).
11. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009; 10: 559-568.
12. Lordick F, Geinitz H, Theisen J et al. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 2006; 64: 1295-1298.
13. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
14. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-870.
15. Crinò L, Dansin E, Garrido P et al. Safety and efficacy of first-line bevacizumabbased therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11: 733-740.
16. Klencke BJ, Bhattacharya S, Samant MK et al. Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). J Clin Oncol 2008; 26 (Suppl): 50s (Abstr 1036).
17. O'Shaughnessy J, Diéras V, Glaspy J et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Res 2009; 69 (Suppl): 512s (Abstr 207).
18. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 26: 3950-3957.
19. O'Shaughnessy JA, Miles DA, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
20. Lang I, Inbar MJ, Greil R et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. J Clin Oncol 2010; 28(15S): 145s (Abst 1126).